EntryPoint Capital’s Maravai LifeSciences MRVI Stock Holding History

EntryPoint Capital’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$241K	Buy	+85,203	New	+$289K	0.07%	565
2025 Q2	–	Sell	-14,423	Closed	-$31.9K	–	735
2025 Q1	$31.9K	Buy	+14,423	New	+$57K	0.01%	648

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EntryPoint Capital's MRVI Position: Q1 2026 in Review

EntryPoint Capital opened a new position in Maravai LifeSciences (MRVI) in Q1 2026: 85,203 shares worth $241K. The stake represents 0.07% of the portfolio and ranks #565 among its holdings. This is a return to the name: EntryPoint Capital previously reported a position in MRVI as recently as Q1 2025.

EntryPoint Capital first reported a position in MRVI in Q1 2025 and has held it in 2 quarters since. 158 funds tracked by Wall St. Rank hold MRVI as of Q1 2026.

EntryPoint Capital held 85,203 shares of Maravai LifeSciences worth $241K as of Q1 2026.
Maravai LifeSciences was a new EntryPoint Capital position in Q1 2026.
Maravai LifeSciences made up 0.07% of EntryPoint Capital's portfolio in Q1 2026, its #565 holding.
EntryPoint Capital first reported a position in Maravai LifeSciences in Q1 2025 and has held it in 2 quarters since.
158 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2026.

Based on EntryPoint Capital's 13F filing for Q1 2026, filed 14 May 2026.